Co-transplantation of bone marrow-derived mesenchymal stem cells and nanospheres containing FGF-2 improve cell survival and neurological function in the injured rat spinal cord

DongAh Shin, William A. Pennant, Do Heum Yoon, Yoon Ha, Keung Nyun Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Spinal cord injury (SCI) is a devastating and irreversible event, and much research using fibroblast growth factor-2 (FGF-2) has been performed to test its capacity to blunt the effects of SCI as well as to provide an environment conducive for SCI repair. Methods: We tested how the in vitro release of FGF-2 from heparin-conjugated poly(L-lactide-co-glycolide) (PLGA)-conjugated nanospheres (HCPNs) affected the growth of human bone marrow-derived mesenchymal stem cells (hBMSCs), as well as the effects of their co-transplantation in an animal model of SCI. Results: Our results showed that sustained, long-term release of FGF-2 from HCPNs significantly increased hBMSCs proliferation in vitro, and that their co-transplantation following rat SCI lead to increased functional improvement, a greater amount of hBMSCs surviving transplantation, and a greater density of neurofilament-positive cells in the injury epicenter. Conclusion: These results suggest a proliferative, protective, and neural inductive potential of FGF-2 for transplanted hBMSCs, as well as a possible role for sustained FGF-2 delivery along with hBMSCs transplantation in the injured spinal cord. Future studies will be required to ascertain the safety FGF-2-containing HCPNs before clinical application.

Original languageEnglish
Pages (from-to)297-303
Number of pages7
JournalActa Neurochirurgica
Volume156
Issue number2
DOIs
Publication statusPublished - 2014 Feb 1

Fingerprint

Nanospheres
Fibroblast Growth Factor 2
Bone Marrow Transplantation
Mesenchymal Stromal Cells
Cell Survival
Spinal Cord
Spinal Cord Injuries
Bone Marrow
Mesenchymal Stem Cell Transplantation
Transplantation
Spinal Cord Regeneration
Polyglactin 910
Intermediate Filaments
Heparin
Animal Models
Cell Proliferation
Safety
Wounds and Injuries
Growth
Research

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

@article{c3083098301245ccacc3e457249135e7,
title = "Co-transplantation of bone marrow-derived mesenchymal stem cells and nanospheres containing FGF-2 improve cell survival and neurological function in the injured rat spinal cord",
abstract = "Background: Spinal cord injury (SCI) is a devastating and irreversible event, and much research using fibroblast growth factor-2 (FGF-2) has been performed to test its capacity to blunt the effects of SCI as well as to provide an environment conducive for SCI repair. Methods: We tested how the in vitro release of FGF-2 from heparin-conjugated poly(L-lactide-co-glycolide) (PLGA)-conjugated nanospheres (HCPNs) affected the growth of human bone marrow-derived mesenchymal stem cells (hBMSCs), as well as the effects of their co-transplantation in an animal model of SCI. Results: Our results showed that sustained, long-term release of FGF-2 from HCPNs significantly increased hBMSCs proliferation in vitro, and that their co-transplantation following rat SCI lead to increased functional improvement, a greater amount of hBMSCs surviving transplantation, and a greater density of neurofilament-positive cells in the injury epicenter. Conclusion: These results suggest a proliferative, protective, and neural inductive potential of FGF-2 for transplanted hBMSCs, as well as a possible role for sustained FGF-2 delivery along with hBMSCs transplantation in the injured spinal cord. Future studies will be required to ascertain the safety FGF-2-containing HCPNs before clinical application.",
author = "DongAh Shin and Pennant, {William A.} and Yoon, {Do Heum} and Yoon Ha and Kim, {Keung Nyun}",
year = "2014",
month = "2",
day = "1",
doi = "10.1007/s00701-013-1963-y",
language = "English",
volume = "156",
pages = "297--303",
journal = "Acta Neurochirurgica",
issn = "0001-6268",
publisher = "Springer Wien",
number = "2",

}

Co-transplantation of bone marrow-derived mesenchymal stem cells and nanospheres containing FGF-2 improve cell survival and neurological function in the injured rat spinal cord. / Shin, DongAh; Pennant, William A.; Yoon, Do Heum; Ha, Yoon; Kim, Keung Nyun.

In: Acta Neurochirurgica, Vol. 156, No. 2, 01.02.2014, p. 297-303.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Co-transplantation of bone marrow-derived mesenchymal stem cells and nanospheres containing FGF-2 improve cell survival and neurological function in the injured rat spinal cord

AU - Shin, DongAh

AU - Pennant, William A.

AU - Yoon, Do Heum

AU - Ha, Yoon

AU - Kim, Keung Nyun

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background: Spinal cord injury (SCI) is a devastating and irreversible event, and much research using fibroblast growth factor-2 (FGF-2) has been performed to test its capacity to blunt the effects of SCI as well as to provide an environment conducive for SCI repair. Methods: We tested how the in vitro release of FGF-2 from heparin-conjugated poly(L-lactide-co-glycolide) (PLGA)-conjugated nanospheres (HCPNs) affected the growth of human bone marrow-derived mesenchymal stem cells (hBMSCs), as well as the effects of their co-transplantation in an animal model of SCI. Results: Our results showed that sustained, long-term release of FGF-2 from HCPNs significantly increased hBMSCs proliferation in vitro, and that their co-transplantation following rat SCI lead to increased functional improvement, a greater amount of hBMSCs surviving transplantation, and a greater density of neurofilament-positive cells in the injury epicenter. Conclusion: These results suggest a proliferative, protective, and neural inductive potential of FGF-2 for transplanted hBMSCs, as well as a possible role for sustained FGF-2 delivery along with hBMSCs transplantation in the injured spinal cord. Future studies will be required to ascertain the safety FGF-2-containing HCPNs before clinical application.

AB - Background: Spinal cord injury (SCI) is a devastating and irreversible event, and much research using fibroblast growth factor-2 (FGF-2) has been performed to test its capacity to blunt the effects of SCI as well as to provide an environment conducive for SCI repair. Methods: We tested how the in vitro release of FGF-2 from heparin-conjugated poly(L-lactide-co-glycolide) (PLGA)-conjugated nanospheres (HCPNs) affected the growth of human bone marrow-derived mesenchymal stem cells (hBMSCs), as well as the effects of their co-transplantation in an animal model of SCI. Results: Our results showed that sustained, long-term release of FGF-2 from HCPNs significantly increased hBMSCs proliferation in vitro, and that their co-transplantation following rat SCI lead to increased functional improvement, a greater amount of hBMSCs surviving transplantation, and a greater density of neurofilament-positive cells in the injury epicenter. Conclusion: These results suggest a proliferative, protective, and neural inductive potential of FGF-2 for transplanted hBMSCs, as well as a possible role for sustained FGF-2 delivery along with hBMSCs transplantation in the injured spinal cord. Future studies will be required to ascertain the safety FGF-2-containing HCPNs before clinical application.

UR - http://www.scopus.com/inward/record.url?scp=84893742338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893742338&partnerID=8YFLogxK

U2 - 10.1007/s00701-013-1963-y

DO - 10.1007/s00701-013-1963-y

M3 - Article

C2 - 24352373

AN - SCOPUS:84893742338

VL - 156

SP - 297

EP - 303

JO - Acta Neurochirurgica

JF - Acta Neurochirurgica

SN - 0001-6268

IS - 2

ER -